Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents
Viruses · 2024
DOI: 10.3390/v16091485 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Yu-Ting Kao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Antiviral Agents, Liver Neoplasms, Hepatitis C, Chronic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Linkou Chang Gung Memorial Hospital, National Science and Technology Council, Chang Gung Medical Research Fund.
Abstract (Originalsprache)
Background
Hepatocellular carcinoma (HCC) remains a significant concern for patients with chronic hepatitis C (HCV), even after achieving a sustained virological response (SVR) with direct-acting antivirals (DAAs) or interferon (IFN)-based therapies. This study compared the risk of HCC in patients with HCV who achieved SVR through the DAA versus IFN regimens.
Methods
A retrospective analysis was conducted on 4806 HCV patients, without coinfection nor prior HCC history, treated at the Chang Gung Memorial Hospital, Taiwan (DAA: 2825, IFN: 1981). Kaplan–Meier and Cox regression analyses with propensity score matching (PSM) were used to adjust for baseline differences.
Results
DAA-treated patients exhibited a higher incidence of HCC than IFN-treated patients before and after PSM (after PSM: annual: 1% vs. 0.5%; 6-year: 6% vs. 3%, p = 0.01). Both DAA and IFN patients had a decreased HCC incidence during follow-up (>3 vs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan.
- School of Medicine, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.
- Department of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.
- Department of Thoracic Surgery, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.
ORCID-Profile: Yu-Ting Kao, Yen-Chun Liu, Yu-Wen Wen, Cheng-Er Hsu, Jennifer Chia-Hung Tai, Wen-Juei Jeng, Chun-Yen Lin, Rong-Nan Chien
Förderung
- Linkou Chang Gung Memorial Hospital
- National Science and Technology Council
- Chang Gung Medical Research Fund
- National Science Council
Zitieren
APA
Kao, Y. T., Liu, Y. C., Cheng, Y. T., Wen, Y. W., Hsieh, Y. C., Hsu, C. E., Su, C. W., Tai, J. C., Chen, Y. C., Jeng, W. J., Lin, C. Y., Chien, R. N., Tai, D. I., & Sheen, I. S. (2024). Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents. Viruses. https://doi.org/10.3390/v16091485
Vancouver
Kao YT, Liu YC, Cheng YT, Wen YW, Hsieh YC, Hsu CE, et al. Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents. Viruses. 2024. doi:10.3390/v16091485
BibTeX
@article{Kao2024,
author = {Kao, Yu-Ting and Liu, Yen-Chun and Cheng, Ya-Ting and Wen, Yu-Wen and Hsieh, Yi-Chung and Hsu, Cheng-Er and Su, Chung-Wei and Tai, Jennifer Chia-Hung and Chen, Yi-Cheng and Jeng, Wen-Juei and Lin, Chun-Yen and Chien, Rong-Nan and Tai, Dar-In and Sheen, I-Shyan},
title = {Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16091485}
}
EUVIMED